In the US alone, SA and MRSA infections burden the healthcare system with approximately $9.5 billion and $20 billion in annual care costs, respectively. 1,2
Moreover, these staggering financial figures only capture a fraction of the burden attributed to MRSA and SA infections. Hospitalized patients endure prolonged stays and suffering, resulting in tangible and intangible costs that add to the considerable price tags associated with the increased morbidity and mortality rates due to MRSA/SA infections.
It’s well established that SA is commonly found as part of the normal flora on the skin and in the respiratory tract of 30% of the population without negative effects on the carrier.3 However, up to 93% of hospital-acquired SA infections are caused by a patient’s own colonized flora.
Colonized patients, specifically, are at increased risk of developing surgical site infections, which lead to prolonged hospital stays, higher costs, and significantly increased risk of death. In fact, SA nasal carriers are 9 times more likely to develop a surgical site infection compared to non-carriers.4 Nasal carriage of SA is also a major risk factor for self-infection in dialysis, ICU, and burn patients.5
A surgical site infection related to undetected SA increases:6,7
A study published in the New England Journal of Medicine demonstrated that programs employing rapid molecular detection of SA colonization followed by targeted decolonization resulted in a 60% reduction in surgical site infections.8
To address the evolving problem of MRSA/SA, growing numbers of hospitals are partnering with microbiology labs to incorporate MRSA/SA screening and surveillance to identify and control these infections.